PT86960B - Processo para a preparacao de conjugados de imunoglobulina - Google Patents

Processo para a preparacao de conjugados de imunoglobulina Download PDF

Info

Publication number
PT86960B
PT86960B PT86960A PT8696088A PT86960B PT 86960 B PT86960 B PT 86960B PT 86960 A PT86960 A PT 86960A PT 8696088 A PT8696088 A PT 8696088A PT 86960 B PT86960 B PT 86960B
Authority
PT
Portugal
Prior art keywords
ida
cells
fragment
monoclonal antibody
antibody
Prior art date
Application number
PT86960A
Other languages
English (en)
Portuguese (pt)
Other versions
PT86960A (pt
Inventor
Ian Farquhar Campbell Mckenzie
Geoffrey Allan Pietersz
Mark John Smyth
Original Assignee
Univ Melbourne
Erba Farmitalia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Melbourne, Erba Farmitalia filed Critical Univ Melbourne
Publication of PT86960A publication Critical patent/PT86960A/pt
Publication of PT86960B publication Critical patent/PT86960B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT86960A 1987-03-11 1988-03-11 Processo para a preparacao de conjugados de imunoglobulina PT86960B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPI080387 1987-03-11
AUPI295587 1987-07-07

Publications (2)

Publication Number Publication Date
PT86960A PT86960A (pt) 1988-04-01
PT86960B true PT86960B (pt) 1992-06-30

Family

ID=25643244

Family Applications (1)

Application Number Title Priority Date Filing Date
PT86960A PT86960B (pt) 1987-03-11 1988-03-11 Processo para a preparacao de conjugados de imunoglobulina

Country Status (29)

Country Link
US (1) US5798097A ( )
JP (1) JP2736255B2 ( )
KR (1) KR0130906B1 ( )
CN (1) CN1045621C ( )
AT (1) AT395375B ( )
AU (1) AU622105B2 ( )
BE (1) BE1001051A4 ( )
CA (1) CA1329156C ( )
CH (1) CH678815A5 ( )
CZ (1) CZ281193B6 ( )
DE (1) DE3808166C2 ( )
DK (1) DK173792B1 ( )
ES (1) ES2006109A6 ( )
FI (1) FI98706C ( )
FR (1) FR2612074B1 ( )
GB (1) GB2203154B ( )
GR (1) GR1000059B ( )
HU (1) HU205266B ( )
IE (1) IE64781B1 ( )
IL (1) IL85688A0 ( )
IT (1) IT8819746A0 ( )
MY (1) MY103231A ( )
NL (1) NL8800610A ( )
NO (1) NO178954C ( )
NZ (1) NZ223834A ( )
PT (1) PT86960B ( )
RU (1) RU2106147C1 ( )
SE (1) SE503402C2 ( )
YU (1) YU46858B ( )

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
DK1119371T3 (da) * 1998-10-09 2011-03-07 Vegenics Ltd Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
EP1343531A2 (en) * 2000-12-21 2003-09-17 McGILL UNIVERSITY Conjugates of antibodies and anticancer drugs
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
CA2522700A1 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
US20080108138A1 (en) * 2006-06-13 2008-05-08 Vermette Patrick Bioactive compositions and their use in cell patterning
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT343811B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
AT346838B (de) * 1975-01-22 1978-11-27 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
GB1500421A (en) * 1975-01-22 1978-02-08 Farmaceutici Italia Optically active anthracyclinones
AT343812B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven daunosaminylderivaten von anthracyclinonen
GB1511680A (en) 1975-11-18 1978-05-24 Farmaceutici Italia Daunosaminyl anthracyclinones
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US4950738A (en) * 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
GB8413464D0 (en) * 1984-05-25 1984-07-04 Erba Farmitalia Anthracycline-anionic polymer conjugates
JPS61155334A (ja) * 1984-12-28 1986-07-15 Teijin Ltd 殺細胞性修飾免疫グロブリン及びその製造方法
FR2584293B1 (fr) * 1985-07-04 1989-03-17 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant

Also Published As

Publication number Publication date
FI881158A0 (fi) 1988-03-11
GB8805865D0 (en) 1988-04-13
NL8800610A (nl) 1988-10-03
DK131588A (da) 1988-09-12
FI98706B (fi) 1997-04-30
FR2612074A1 (fr) 1988-09-16
NO881105D0 (no) 1988-03-11
GR1000059B (el) 1990-06-27
CZ161288A3 (en) 1996-07-17
IL85688A0 (en) 1988-08-31
YU48288A (en) 1989-08-31
DK131588D0 (da) 1988-03-11
NL195078C ( ) 2003-07-30
PT86960A (pt) 1988-04-01
YU46858B (sh) 1994-06-24
SE8800886D0 (sv) 1988-03-11
AU1288188A (en) 1988-09-15
FI98706C (fi) 1997-08-11
KR0130906B1 (ko) 1998-04-23
DK173792B1 (da) 2001-11-05
JPS63301832A (ja) 1988-12-08
IT8819746A0 (it) 1988-03-11
CZ281193B6 (cs) 1996-07-17
DE3808166C2 (de) 1997-08-28
IE64781B1 (en) 1995-09-06
KR880010775A (ko) 1988-10-24
CA1329156C (en) 1994-05-03
ES2006109A6 (es) 1989-04-01
GB2203154A (en) 1988-10-12
RU2106147C1 (ru) 1998-03-10
BE1001051A4 (fr) 1989-06-20
CN1045621C (zh) 1999-10-13
FR2612074B1 (fr) 1991-06-21
HU205266B (en) 1992-04-28
AU622105B2 (en) 1992-04-02
GB2203154B (en) 1991-06-26
ATA67488A (de) 1992-05-15
SE503402C2 (sv) 1996-06-10
CN88101810A (zh) 1988-11-09
DE3808166A1 (de) 1988-09-22
FI881158A (fi) 1988-09-12
GR880100148A (en) 1989-01-31
CH678815A5 ( ) 1991-11-15
US5798097A (en) 1998-08-25
SE8800886L (sv) 1989-09-12
AT395375B (de) 1992-12-10
JP2736255B2 (ja) 1998-04-02
NO881105L (no) 1988-09-12
IE880701L (en) 1988-09-11
NO178954C (no) 1996-07-10
NO178954B (no) 1996-04-01
MY103231A (en) 1993-05-29
NZ223834A (en) 1990-05-28
HUT46547A (en) 1988-11-28

Similar Documents

Publication Publication Date Title
US4880935A (en) Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4485093A (en) Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
PT89683B (pt) Processo para a preparacao de imunoconjugados de antraciclina comportando novos ligandos
PT91371B (pt) Processo para a preparacao de conjugados de medicamentos citotoxicos, nomeadamente conjugados de medicamentos de metotrexato
Smyth et al. Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies
Pietersz et al. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates
PT86960B (pt) Processo para a preparacao de conjugados de imunoglobulina
PT94064B (pt) Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem
DK141773B (da) Fremgangsmåde til fremstilling af et antitumormiddel.
EP0476408A1 (en) Chemical conjugation of morpholino anthracyclines to antibodies
US20040062764A1 (en) Chemoprotectant for gastric toxicity
WO2002017962A2 (en) Chemoprotectant for gastric toxicity
RU2009500C1 (ru) Способ получения цитотоксического коньюгата
US20080095802A1 (en) Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients iwth transplanted organs, B) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and C) in vitaminpbinding proteins as drug carriers in the diagnosis and treatment of cancer
CA2414401A1 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
AU2007201744A1 (en) Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients with transplanted organs, B) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and C) in vitamin binding proteins as drug carriers in the diagnosis and treatment of cancer
WO1992014758A1 (en) Conjugate molecules

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19911206

PC3A Transfer or assignment

Free format text: 961212 PHARMACIA & UPJOHN S.P.A. IT

TE3A Change of address (patent)
PC3A Transfer or assignment

Free format text: PHARMACIA ITALIA S.P.A. IT

Effective date: 20021002

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20080311